Skip to content

Clinical study of the effect of motorized rising bed training on hemodynamic blood flow in stroke patients

Clinical study of the effect of motorized rising bed training on hemodynamic blood flow in stroke patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096329
Enrollment
Unknown
Registered
2025-01-22
Start date
2023-11-30
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Observation group:None

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Meets diagnostic criteria for stroke; (2) Vital signs are stable; (3) Age > 18 years; (4) Duration of the disease is more than 48 hours and less than 6 months; (5) Understand and actively participate in the assessment and training program.

Exclusion criteria

Exclusion criteria: (1) Unstable vital signs: expected maximal heart rate 180 beats/min; new malignant arrhythmia; new myocardial infarction with new initiation of antiarrhythmic medication or evidence of myocardial infarction combined with electrocardiographic or myocardial enzyme profiles; blood pressure SBP>180 mm Hg or DBP>110 mm Hg MAP40 breaths/min; mechanical ventilation FiO2>=0.60 PEEP>=10 cmH2O; human-machine asynchrony; change in mechanical ventilation to assisted or pressure support mode; difficulty in maintaining a fixed artificial airway; (2) Progressive stroke; acute phase of stroke; transient ischemic attack; patients with history of traumatic brain injury, encephalitis, tuberculous meningitis, and other history of parenchymal and central nervous involvement; (3) Acute coronary syndrome, decompensated heart failure, uncontrolled severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.) or high degree of atrioventricular block, severe heart valve disease, hypertrophic obstructive cardiomyopathy, active myocarditis, pericarditis, and other serious cardiac diseases; (4) Those with severe hepatic or renal insufficiency, including glomerular filtration rate GFR = 200 U/L, or aspartate aminotransferase AST >=200 U/L; (5) Combination of other serious diseases, such as malignant tumor, chronic kidney disease end stage, mental disorder, severe malnutrition, etc; (6) Lower limb fracture not healed, severe osteoporosis; (7) Pregnant or lactating women; (8) Participating in other clinical trials of drugs or medical devices during the same period.

Design outcomes

Primary

MeasureTime frame
Blood pressure levels at different bed angles;

Secondary

MeasureTime frame
Heart rate;Cardiac output;Subjective symptoms (dizziness, fatigue);

Countries

China

Contacts

Public ContactMingchao Zhou, Lirong Wang

Shenzhen Second People's Hospital

zhoumc06@email.szu.edu.cn+86 186 7670 2417

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 3, 2026